Patient Travel Concerns After Treatment with 177Lu-DOTATATE
| Autor: | Boris G. Naraev, David J. Mercer, James K. Underwood, Thorvardur R. Halfdanarson, Josh Mailman, Ayse Tuba Kendi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Advanced Accelerator Applications business.industry Neuroendocrine tumors medicine.disease 030218 nuclear medicine & medical imaging Food and drug administration 03 medical and health sciences 0302 clinical medicine Somatostatin 030220 oncology & carcinogenesis Internal medicine medicine 177Lu-DOTATATE Radiology Nuclear Medicine and imaging business After treatment |
| Zdroj: | Journal of Nuclear Medicine. 61:496-497 |
| ISSN: | 2159-662X 0161-5505 |
| Popis: | Since its approval by the U.S. Food and Drug Administration in late January 2018, 177Lu-labeled DOTATATE (Lutathera; Advanced Accelerator Applications, a Novartis company) has been used for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors by |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|